Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 9/20 | 0.38 |
| ▸ | RXRB | P28702 | 8/20 | 0.38 |
| ▸ | RXRG | P48443 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233736 | 0.81 | EPHX2 (0.40) | RXRARXRBRXRGKMT2AALDH1A1 | |
| SCHEMBL4228142 | 0.74 | RAB9A (0.47) | HRH3RXRARAB9AALDH1A1 | |
| SCHEMBL4240943 | 0.73 | CA12 (0.49) | RAB9AKMT2A | |
| SCHEMBL4233804 | 0.73 | TAS1R3 (0.38) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9640284 | 0.72 | CHRM2 (0.46) | KMT2A | |
| SCHEMBL1851579 | 0.70 | KMT2A (0.39) | POLBKMT2AALDH1A1 | |
| SCHEMBL4238428 | 0.67 | RXRA (0.43) | RXRARXRBRXRGNPC1RAB9A | |
| SCHEMBL4236757 | 0.67 | EPHX2 (0.39) | RXRARXRBRXRGKMT2AALDH1A1 | |
| SCHEMBL1750107 | 0.67 | KMT2A (0.47) | RXRARXRBRXRGNPC1RAB9A | |
| SCHEMBL1749785 | 0.67 | KMT2A (0.51) | RXRARXRBRXRGNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885RXRA 735/4885RXRB 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.